Optimizing management of ruxolitinib in patients with myelofibrosis: The need for individualized dosing

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Mesa, Ruben A ^a   Cortes, Jorge ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anemia; COMFORT I; Dosing; JAK inhibitor; Myelofibrosis; Ruxolitinib; Thrombocytopenia

Indexed keywords

AZACITIDINE; HEMOGLOBIN; LENALIDOMIDE; PLACEBO; RUXOLITINIB;

ANEMIA; BLEEDING; CLINICAL PRACTICE; CYTOPENIA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEUTROPENIA; NEUTROPHIL COUNT; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANEMIA; HUMANS; INDIVIDUALIZED MEDICINE; PRIMARY MYELOFIBROSIS; PYRAZOLES; THROMBOCYTOPENIA;

EID: 84886871385     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-79     Document Type: Review

References (25)

1. Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium. Abdel-Wahab O, Pardanani A, Bernard OA, Finazzi G, Crispino JD, Gisslinger H, Kralovics R, Odenike O, Bhalla K, Gupta V, Barosi G, Gotlib J, Guglielmelli P, Kiladjian JJ, Noel P, Cazzola M, Vannucchi AM, Hoffman R, Barbui T, Thiele J, Van Etten RA, Mughal T, Tefferi A, Am J Hematol 2012 87 562 568 10.1002/ajh.23169 22460584
2. MPN-associated myelofibrosis (MPN-MF). Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale RP, Leuk Res 2011 35 12 13 10.1016/j.leukres. 2010.07.019 20684988
3. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Abdel-Wahab OI, Levine RL, Annu Rev Med 2009 60 233 245 10.1146/annurev.med.60. 041707.160528 18947294
4. Clinical and laboratory features of myelofibrosis and limitations of current therapies. Gregory SA, Mesa RA, Hoffman R, Shammo JM, Clin Adv Hematol Oncol 2011 9 1 16
5. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A, J Clin Oncol 2011 29 1356 1363 10.1200/JCO.2010.32.9490 21300928
6. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J, Bourantas KL, Br J Haematol 2005 130 709 715 10.1111/j.1365-2141.2005.05674.x 16115126 (Pubitemid 43906643)
7. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Wang JC, Chang TH, Goldberg A, Novetsky AD, Lichter S, Lipton J, Exp Hematol 2006 34 1617 1623 10.1016/j.exphem.2006.07.004 17157157 (Pubitemid 44838997)
8. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S, Nat Rev Drug Discov 2011 10 127 140 10.1038/nrd3264 21283107
9. Genetic and epigenetic complexity in myeloproliferative neoplasms. Cross NC, Hematology Am Soc Hematol Educ Program 2011 2011 208 214 10.1182/asheducation-2011.1.208 22160036
10. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Oh ST, Gotlib J, Expert Rev Hematol 2010 3 323 337 10.1586/ehm.10.28 21082983
11. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Mascarenhas J, Mughal TI, Verstovsek S, Curr Med Chem 2012 19 4399 4413 10.2174/092986712803251511 22830345
12. JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation? Santos FP, Verstovsek S, Anticancer Agents Med Chem 2012 12 1098 1109 10.2174/187152012803529727 22583424
13. Splenomegaly in myelofibrosis-new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S, J Hematol Oncol 2012 5 43 10.1186/1756-8722-5-43 22852872
14. The evolving treatment paradigm in myelofibrosis. Mesa RA, Leuk Lymphoma 2013 54 242 251 10.3109/10428194.2012.710905 22793267
15. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S, Blood 2010 115 3109 3117 10.1182/blood-2009-04-214957 20130243
16. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM, N Engl J Med 2012 366 799 807 10.1056/NEJMoa1110557 22375971
17. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G, N Engl J Med 2012 366 787 798 10.1056/NEJMoa1110556 22375970
18. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. Talpaz M, Paquette R, Afrin L, Hamburg S, Prchal JT, Jamieson K, Terebelo H, Ortega G, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O'Neill P, Erickson-Viitanen S, Leopold L, Sandor VA, Levy RS, Kantarjian HM, Verstovsek S, J Hematol Oncol 2013 in press
19. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM, Haematologica 2013 Epub ahead of print
20. Long-term safety, efficacy, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF) [abstract]. Cervantes F, Kiladjian J-J, Niederwieser D, Sirulnik A, Stalbovskaya V, McQuity M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Gisslinger H, Vannucchi AM, Knoops L, Harrison CN, Blood 2012 120 801
21. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A, N Engl J Med 2010 363 1117 1127 10.1056/NEJMoa1002028 20843246
22. Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian H, Mesa RA, Onco Targets Ther 2013 6 1 9 23319867
23. Azacitidine adverse effects in patients with myelodysplastic syndromes. San Miguel Amigo L, Franco Osorio R, Mercadal Vilchez S, Martinez-Frances A, Adv Ther 2011 28 4 6 11 21688207
24. Efficacy of lenalidomide in myelodysplastic syndromes. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB, N Engl J Med 2005 352 549 557 10.1056/NEJMoa041668 15703420 (Pubitemid 40204668)
25. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Giagounidis A, Fenaux P, Mufti GJ, Muus P, Platzbecker U, Sanz G, Cripe L, Von Lilienfeld-Toal M, Wells RA, Ann Hematol 2008 87 345 352 10.1007/s00277-008-0449-0 18265982